BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND CDH1, uvomorulin, 999, P12830, ENSG00000039068, CDHE, Arc-1, UVO, LCAM, CD324, ECAD AND Treatment
48 results:

  • 1. Contrast-enhanced CT-based radiomics differentiate anterior mediastinum lymphoma from thymoma without myasthenia gravis and calcification.
    Huang X; Wang X; Liu Y; Wang Z; Li S; Kuang P
    Clin Radiol; 2024 Apr; 79(4):e500-e510. PubMed ID: 38242804
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Mori T; Osumi T; Kada A; Ohki K; Koga Y; Fukano R; Fujita N; Mitsui T; Mori T; Saito AM; Nakazawa A; Kobayashi R; Sekimizu M
    Eur J Haematol; 2024 Apr; 112(4):585-593. PubMed ID: 38112205
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. CXCR4-directed PET/CT with [
    Dreher N; Hahner S; Fuß CT; Schlötelburg W; Hartrampf PE; Serfling SE; Schirbel A; Samnick S; Higuchi T; Weich A; Lapa C; Rosenwald A; Buck AK; Kircher S; Werner RA
    Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1383-1394. PubMed ID: 38082196
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. A novel NET-related gene signature for predicting DLBCL prognosis.
    Shi H; Pan Y; Xiang G; Wang M; Huang Y; He L; Wang J; Fang Q; Li L; Liu Z
    J Transl Med; 2023 Sep; 21(1):630. PubMed ID: 37716978
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Infectious events in pediatric patients with acute lymphoblastic leukemia/lymphoma undergoing evaluation for fever without severe neutropenia.
    Patel PA; DeGroote NP; Jackson K; Cash T; Castellino SM; Jaggi P; Esbenshade AJ; Miller TP
    Cancer; 2022 Dec; 128(23):4129-4138. PubMed ID: 36238979
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
    Pagel JM; Soumerai JD; Reddy N; Jagadeesh D; Stathis A; Asch A; Salman H; Kenkre VP; Iasonos A; Llorin-Sangalang J; Li J; Zelenetz AD
    Lancet Oncol; 2022 Aug; 23(8):1021-1030. PubMed ID: 35835137
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020.
    Desai A; Scheckel C; Jensen CJ; Orme J; Williams C; Shah N; Leventakos K; Adjei AA
    JAMA Netw Open; 2022 Jan; 5(1):e2144923. PubMed ID: 35076701
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
    Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study.
    Lin N; Zhang M; Bai H; Liu H; Cui J; Ke X; Zhang H; Liu L; Yan D; Jiang Y; Zang A; Qi J; Wang L; Liu Z; Xu B; Zhang Y; Zhang Z; Zhao X; Hu C; Yang S; Zhou H; Shi J; Shao Z; Xiang Y; Zhu J; Song Y; Zhu J
    Eur J Cancer; 2022 Mar; 164():117-126. PubMed ID: 34462189
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma.
    McBride A; MacDonald K; Abraham I
    Leuk Res; 2021 Jul; 106():106591. PubMed ID: 33957339
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Suberoylanilide Hydroxamic Acid (SAHA) Reduces Fibrosis Markers and Deactivates Human Stellate Cells via the Epithelial-Mesenchymal Transition (EMT).
    Özel M; Baskol M; Akalın H; Baskol G
    Cell Biochem Biophys; 2021 Jun; 79(2):349-357. PubMed ID: 33689126
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Selective dysregulation of ABC transporters in methotrexate-resistant leukemia T-cells can confer cross-resistance to cytarabine, vincristine and dexamethasone, but not doxorubicin.
    Aberuyi N; Rahgozar S; Pourabutaleb E; Ghaedi K
    Curr Res Transl Med; 2021 Jan; 69(1):103269. PubMed ID: 33071214
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Ultrasonic irradiation and SonoVue microbubbles-mediated RNA interference targeting PRR11 inhibits breast cancer cells proliferation and metastasis, but promotes apoptosis.
    Luo H; Li J; Lin Q; Xiao X; Shi Y; Ye X; Wei Z; Liu Y; Xu J
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33057583
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. [Efficacy and safety of hepatitis B re-vaccination in children after completion of chemotherapy and(or) hematopoietic stem cell transplantation].
    Yuan Q; Zhou F; Zhang H; Cao Q; Chen WJ; Fei Y; Luo CY; Gao YJ
    Zhonghua Er Ke Za Zhi; 2020 Oct; 58(10):802-806. PubMed ID: 32987458
    [No Abstract]    [Full Text] [Related]  

  • 16. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
    Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.
    Lyapichev KA; Bah I; Huen A; Duvic M; Routbort MJ; Wang W; Jorgensen JL; Medeiros LJ; Vega F; Craig FE; Wang SA
    Cytometry B Clin Cytom; 2021 Mar; 100(2):183-191. PubMed ID: 32667737
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. A presentation, treatment, and survival analysis of primary cardiac lymphoma cases reported from 2009 to 2019.
    Chen H; Qian S; Shi P; Liu L; Yang F
    Int J Hematol; 2020 Jul; 112(1):65-73. PubMed ID: 32285360
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
    Felip E; de Braud FG; Maur M; Loong HH; Shaw AT; Vansteenkiste JF; John T; Liu G; Lolkema MP; Selvaggi G; Giannone V; Cazorla P; Baum J; Balbin OA; Wang LV; Lau YY; Scott JW; Tan DS
    J Thorac Oncol; 2020 Mar; 15(3):392-403. PubMed ID: 31634667
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Mitotic slippage: an old tale with a new twist.
    Sinha D; Duijf PHG; Khanna KK
    Cell Cycle; 2019 Jan; 18(1):7-15. PubMed ID: 30601084
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.